Schizophrenia Trial, Recruiting NCT07493551 Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. Condition: Schizophrenia
Back to Schizophrenia

Schizophrenia Trial, Recruiting

NCT07493551
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 to 65 years old (inclusive).
  • People who have been diagnosed with schizophrenia according to ICD-10 diagnostic criteria before the screening stage.
  • People who meet specific weight requirements: male participants weighing at least 50.0 kg, and female participants weighing at least 45.0 kg, with a body mass index (BMI) between 19.0 and 35.0 kg/m².
  • People whose schizophrenia symptoms are rated as relatively mild at both the screening and baseline stages, based on two standard clinical assessment tools (the PANSS and CGI-S scales) (confirm with trial site).
  • People who, along with their guardians if applicable, are willing to sign a consent form and are able to follow the requirements of the study.

Who may not be able to join:

  • People with a known allergy, or a clear history of allergies, to the trial drugs or their ingredients.
  • People with heart, liver, kidney, digestive, psychiatric, or neurological conditions that the study doctor believes could affect safe participation in the trial.
  • People with a history of tardive dyskinesia (an involuntary movement disorder that can be associated with certain medications).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Gang Wang, M.D., Beijing Anding Hospital Capital Medical University

Phone: 86-0311-69085587

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Registry
ClinicalTrials.gov
Start date
9 October 2024
Est. completion
31 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Cmax,ss,; AUCτ,ss

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov